<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00171444</url>
  </required_header>
  <id_info>
    <org_study_id>CVAH631DFR06</org_study_id>
    <nct_id>NCT00171444</nct_id>
  </id_info>
  <brief_title>Comparison of Two Treatment Strategies in Hypertensive Patients</brief_title>
  <official_title>A 8-week Comparison, in a General Practice Setting, Between Two Treatment Strategies With Valsartan and Valsartan/HCTZ Aiming at Normalizing de Novo Hypertensive Patients Who Are Not Adequately Controlled With Their Monotherapy or Biotherapy Treatment or Experiencing Unacceptable Side-effects, According to Their Baseline Blood Pressure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether a specific training of General Practitioners
      (Family Physicians) regarding the new official guidelines for the treatment of hypertension
      results in a higher control of high Blood pressure in their patient population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">May 2005</completion_date>
  <primary_completion_date type="Actual">May 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure less than 140/90 mmHg in non-diabetic patients, or less than 130/80 mmHg in patients with diabetes or kidney disease, after 8 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline systolic blood pressure after 8 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline diastolic blood pressure after 8 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure less than 90 mmHg or reduction in diastolic blood pressure greater than 10 mmHg</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure less than 140 mmHg or reduction in diastolic blood pressure greater than 15 mmHg</measure>
  </secondary_outcome>
  <enrollment type="Actual">4445</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Medical education</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Male or female patients &gt;18 years of age

               -  Hypertension defined by MSDBP ≥ 90 and /or MSSBP ≥ 140 mmHg for untreated
                  patients, patients on diet and exercise, patients on current anti-hypertensive
                  monotherapy or bitherapy treatment who remain uncontrolled or patients
                  experiencing unacceptable side-effects,

        Exclusion Criteria:

          -  • Severe hypertension, secondary hypertension, type 1 diabetes mellitus

               -  History of congestive heart failure, unstable coronary insufficiency, life
                  threatening arrhythmia, significant valvular disease, second or third degree
                  heart block etc.

               -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novatis Pharmaceuticals</affiliation>
  </overall_official>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>November 7, 2011</last_update_submitted>
  <last_update_submitted_qc>November 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypertension,</keyword>
  <keyword>valsartan+hydrochlorothiazide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

